Bui, B. N. http://orcid.org/0000-0003-3542-6215
Ardisasmita, A. I. http://orcid.org/0000-0001-8527-4585
van de Vliert, F. H.
Abendroth, M. S. http://orcid.org/0009-0004-4350-3449
van Hoesel, M.
Mackens, S. http://orcid.org/0000-0001-7012-0436
Fuchs, S. A. http://orcid.org/0000-0001-9147-2406
Nieuwenhuis, E. E. S. http://orcid.org/0000-0001-8094-1211
Broekmans, F. J. M. http://orcid.org/0000-0003-1366-2727
Steba, G. S. http://orcid.org/0000-0003-2652-0760
Article History
Received: 2 February 2024
Accepted: 13 June 2024
First Online: 12 July 2024
Declarations
:
: Ethical approval was obtained from the Institutional Review Board of the University Medical Centre (UMC) Utrecht (15–495 (30 November 2015) and 17–592 (28 September 2017)) and the Biobank Research Ethics Committee of the UMC Utrecht (17–789 (15 March 2018)). Written informed consent was obtained from all study participants.
: The SCRATCH and SCRaTCH-OFO trials and the current endometrial organoid transcriptome study received funding from public sources and Merck, but none of these sources had input in the study design and analysis. In addition, several authors report having received personal fees for consultations, conference attendance, and travel as follows: BB from Gedeon Richter Benelux and Guerbet; GS from Guerbet; and SM from Abbott Pharmaceuticals, Ferring, Merck, Oxolife and IBSA. FB is a paid member of the advisory boards of Merck and Ferring and also received speakers’ fees from Besins Healthcare, Cooper Surgical and Merck. All of these personal fees were unrelated to the study reported in this manuscript. The remaining authors declare no conflicts of interest relevant to this study.